Autologous hematopoietic stem cell transplantation for type 1 diabetes

Ann N Y Acad Sci. 2008 Dec;1150:220-9. doi: 10.1196/annals.1447.048.

Abstract

In this review, we present (1) the scientific basis for the use of high-dose immunosuppression followed by autologous peripheral blood hematopoietic stem cell transplantation for newly diagnosed type 1 diabetes (T1D); (2) an update of the clinical and laboratory outcome of 20 patients transplanted at the University Hospital of the Ribeirão Preto Medical School, University of São Paulo, Brazil, and followed up to January/2008, including 4 relapses among 19 patients without previous ketoacidosis; (3) a commentary on criticisms to our article that appeared in four articles from the scientific literature; and (4) a discussion of the prospectives for cellular therapy for T1D.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 1 / therapy*
  • Hematologic Diseases / complications
  • Hematologic Diseases / therapy
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Immunosuppression / methods
  • Mice
  • Models, Biological
  • Transplantation, Autologous